(Q43188221)

15 November 2017

0 references

Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype? (English)

1 reference

15 November 2017

1 reference

Uwe Fuhr

1

1 reference

15 November 2017

publication date

20 January 2010

1 reference

The Journal of Clinical Pharmacology

15 November 2017

published in

1 reference

15 November 2017

volume

50

1 reference

15 November 2017

issue

4

1 reference

15 November 2017

page(s)

370-372

1 reference

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

15 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

CYP2D6 phenotype prediction from genotype: which system is the best?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Target concentration intervention: beyond Y2K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009353605

21 January 2018

Identifiers

DOI

10.1177/0091270009353605

1 reference

15 November 2017

1 reference